Wednesday, February 21, 2024 1:06:17 PM
The base prospectus immediately follows this explanatory note. The specific terms of any securities to be offered pursuant to the base prospectus other than the shares under the sales agreement will be specified in a prospectus supplement to the base prospectus. The specific terms of the securities to be issued and sold under the sales agreement are specified in the sales agreement prospectus that immediately follows the base prospectus. The $100,000,025 of common stock that may be offered, issued and sold under the sales agreement prospectus is included in the $300.0 million of securities that may be offered, issued and sold by us under the base prospectus. If the sales agreement with Jefferies LLC is terminated, any portion of the $100,000,025 of common stock included in the sales agreement prospectus that is not sold pursuant to the sales agreement will become available for sale in other offerings pursuant to the base prospectus and a corresponding prospectus supplement, and if no shares are sold under the sales agreement, the full $100,000,025 of securities may be sold in other offerings pursuant to the base prospectus and a corresponding prospectus supplement.
https://www.otcmarkets.com/filing/html?id=17263201&guid=o0d-kFHS95BWJth
Recent VTYX News
- Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024 • GlobeNewswire Inc. • 05/02/2024 08:05:00 PM
- The Gross Law Firm Reminds Ventyx Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYX • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Ventyx Biosciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 30, 2024 to Discuss Your Rights - VTYX • PR Newswire (US) • 04/19/2024 10:00:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 30, 2024 in Ventyx Biosciences, Inc. Lawsuit - VTYX • PR Newswire (US) • 04/16/2024 09:45:00 AM
- The Gross Law Firm Reminds Ventyx Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYX • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Investors in Ventyx Biosciences, Inc. Should Contact The Gross Law Firm Before April 30, 2024 to Discuss Your Rights - VTYX • PR Newswire (US) • 04/09/2024 10:10:00 AM
- Investors who lost money on Ventyx Biosciences, Inc.(VTYX) should contact The Gross Law Firm about pending Class Action - VTYX • PR Newswire (US) • 04/05/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 30, 2024 in Ventyx Biosciences, Inc. Lawsuit - VTYX • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Ventyx Biosciences, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - VTYX • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 01:01:59 PM
- Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event • GlobeNewswire Inc. • 03/11/2024 11:00:00 AM
- The Gross Law Firm Reminds Ventyx Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYX • PR Newswire (US) • 03/11/2024 09:45:00 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 03/08/2024 09:05:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 01:45:01 PM
- Ventyx Biosciences Announces $100 Million Private Placement of Common Stock • GlobeNewswire Inc. • 03/07/2024 01:00:19 PM
- Class Action Filed Against Ventyx Biosciences, Inc. (VTYX) Seeking Recovery for Investors - Contact The Gross Law Firm • PR Newswire (US) • 03/07/2024 10:45:00 AM
- Ventyx Biosciences to Participate in Two Upcoming Investor Conferences • GlobeNewswire Inc. • 03/06/2024 01:00:00 PM
- Ventyx Biosciences to Host Virtual Investor Event on March 11, 2024 • GlobeNewswire Inc. • 03/04/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:08:05 PM
- Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress • GlobeNewswire Inc. • 02/27/2024 09:01:00 PM
- Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO) • GlobeNewswire Inc. • 02/22/2024 12:00:00 PM
- Form POSASR - Post-effective Amendment to an automatic shelf registration statement • Edgar (US Regulatory) • 02/13/2024 09:09:32 PM
- Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/06/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 11:26:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 11:23:42 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM